NEW YORK (GenomeWeb) – Protagen said today it has entered a collaboration with the Gustave Roussy Institute of Oncology to identify biomarkers for immune system-related side effects in cancer patients treated with checkpoint inhibitors.

Under the collaboration, the parties will use Protagen's SeroTag platform, which simultaneously measures autoantibody levels for thousands of antigens, to test cancer immunotherapy patients for markers linked to immune-related adverse events (irAEs) and, ultimately, develop a risk-profiling test for patients undergoing immunotherapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.